INDV and the Shift to Long-Acting Opioid Use Disorder Care in 2026

INDV is benefiting from a market shift toward long-acting injectable care for opioid use disorder, with monthly treatments improving adherence versus daily regimens. Current penetration for long-acting injectables remains about 9%, leaving meaningful growth potential into 2026 and beyond if adoption expands among providers. Management expects Sublocade dispense growth to the mid-teens percentage range in 2026, up from 7% in 2025, aided by stronger commercial execution and demand creation. Sublocade benefits from broad payer coverage, with more than 88% of payors covering the therapy, and Indivior held a 76% category share in Q1 2026. In 2025, Indivior reported total net revenues of $1.2 billion, with Sublocade contributing $856 million, and Q1 2026 momentum continued. In Q1 2026, Sublocade net revenues rose 32% to $232 million, while dispense units grew 20% YoY and prescriber base broadened. About 31,800 new patients started Sublocade in the quarter, bringing 12-month treated to 191,600. The firm also signaled strategic shifts, winding down INDV-2000 and revising its INDV-6001 plans while pursuing external business development to supplement its pipeline.